Company

Astellas Pharma Partners With AI Proteins in Computational Drug Discovery Deal Worth Over USD 400 Million – Access to Miniprotein Design Platform to Strengthen Early-Stage Pipeline
AIAI Proteins

Astellas Pharma Partners With AI Proteins in Computational Drug Discovery Deal Worth Over USD 400 Million – Access to Miniprotein Design Platform to Strengthen Early-Stage Pipeline

Astellas Pharma Inc. (TYO: 4503) announced a collaboration with AI Proteins, a Boston‑based computational drug discovery company, in a deal with a total potential value exceeding USD 400 million. Under…

Roche Reports 9M 2026 Sales of CHF 46.493 Billion, Up 6% at CER – Ocrevus Leads as Pharmaceuticals Division Drives Growth and Full-Year Guidance Is Confirmed

Roche Reports 9M 2026 Sales of CHF 46.493 Billion, Up 6% at CER – Ocrevus Leads as Pharmaceuticals Division Drives Growth and Full-Year Guidance Is Confirmed

European Commission Approves Novartis' Cosentyx for Polymyalgia Rheumatica – First and Only IL-17A Inhibitor for Adult PMR in Europe

European Commission Approves Novartis’ Cosentyx for Polymyalgia Rheumatica – First and Only IL-17A Inhibitor for Adult PMR in Europe

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
CF PharmTechClinical trial approval / initiation

CF PharmTech Wins NMPA Approval for Olopatadine Mometasone Combo Trial – Fixed-Dose Nasal Spray Targets Moderate-to-Severe Allergic Rhinitis

CancerClinical trial approval / initiation

Dongcheng Pharma Doses First Patient in 225Ac-LNC1011 Phase I/II Trial – PSMA-Targeted Alpha Radiotherapy for Metastatic Prostate Cancer

ADC / XDCBio-Thera Solutions

Bio-Thera Wins NMPA Approval for BAT8008 BAT1006 Trastuzumab Combo Trial – Dual HER2 Trop2 Targeting in Advanced Solid Tumors

Novo Nordisk's IcoSema Wins NMPA Approval – Once-Weekly Insulin-Semaglutide Combo Targets China Type 2 Diabetes Market
DiabetesHot targets

Novo Nordisk’s IcoSema Wins NMPA Approval – Once-Weekly Insulin-Semaglutide Combo Targets China Type 2 Diabetes Market

Show More